RIMADYL by Roche is clinical pharmacology carprofen is a non-narcotic, non-steroidal anti-inflammatory agent with characteristic analgesic and antipyretic activity approximately equipotent to indomethacin in animal models. First approved in 1987.
Drug data last refreshed Just now · AI intelligence enriched 3w ago
RIMADYL (carprofen) is a non-narcotic, non-steroidal anti-inflammatory agent approved for veterinary use in dogs, functioning as a COX-2 selective inhibitor to provide anti-inflammatory, analgesic, and antipyretic activity. It is used to manage pain and inflammation in canine patients, with a mechanism similar to indomethacin. The drug is rapidly absorbed orally with peak concentrations achieved within 1–3 hours and a terminal half-life of approximately 8 hours.
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), signaling potential contraction of commercial team and shift toward lifecycle management strategies.
CLINICAL PHARMACOLOGY Carprofen is a non-narcotic, non-steroidal anti-inflammatory agent with characteristic analgesic and antipyretic activity approximately equipotent to indomethacin in animal models. The mechanism of action of carprofen, like that of other NSAIDs, is believed to be associated…
Worked on RIMADYL at Roche? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
RIMADYL positions career professionals in a mature veterinary pharmaceutical market facing imminent generic competition and declining exclusivity. Roles on this product involve defensive commercial strategy, customer retention, and potential transition planning rather than growth or innovation-driven initiatives.